Rapid reduction of BCR ‐ABL1 transcript predicts deep molecular response in dasatinib‐treated chronic‐phase chronic myeloid leukaemia patients

ConclusionsPrimary treatment of CML‐CP with dasatinib enabled early achievement of MMR and DMR, particularly in elderly patients, with high safety. Furthermore, RR‐BCR‐ABL13m was found to be a more useful predictor of DMR than HT‐BCR‐ABL1 and BCR‐ABL1 IS.This article is protected by copyright. All rights reserved.

Source: European Journal of Haematology - September 1, 2017 Category: Hematology Authors: Kazunori Murai, Kohei Yamaguchi, Shigeki Ito, Takuto Miyagishima, Motohiro Shindo, Kentaro Wakasa, Mitsue Inomata, Takahiro Nagashima, Takeshi Kondo, Nozomu Fujimoto, Satoshi Yamamoto, Masakatsu Yonezumi, Tatsuo Oyake, Kowata Shugo, Yasuhiko Tsukushi, Tak Tags: Original Article Source Type: research